行情

SLS

SLS

Galena生物制药
NASDAQ

实时行情|Nasdaq Last Sale

4.290
-0.160
-3.60%
盘后: 4.325 +0.035 +0.82% 19:05 12/11 EST
开盘
4.420
昨收
4.450
最高
4.460
最低
4.110
成交量
52.78万
成交额
--
52周最高
89.50
52周最低
3.673
市值
2,090.06万
市盈率(TTM)
-0.0017
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SLS 新闻

  • SELLAS Life Sciences Group, Inc. (SLS) CEO Angelos Stergiou at 12th Annual LD Micro Main Event Conference (Transcript)
  • Seeking Alpha - Transcript.6小时前
  • 12th Annual LD Micro Event (Stream Link)
  • Benzinga.14小时前
  • SELLAS to Present at the 12th Annual LD Micro Main Event
  • GlobeNewswire.12/04 13:00
  • 趣头条Q3净营收14.07亿元 超市场预期
  • 新浪美股.12/03 11:10

更多

所属板块

制药
+0.17%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

SLS 简况

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
展开

Webull提供Sellas Life Sciences Group Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。